News
Quotient Sciences Completes Major Expansion of Drug Substance Manufacturing Facility
Read Announcement
Molecule to cure. Fast.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast.
Because humanity needs solutions, fast.
Watch our video
Welcome to Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.
Our services
At Quotient Sciences, we’ve streamlined the drug development process by providing pre-formulation screening, formulation development, first-in-human trials, and clinical & commercial manufacturing services all at one CDMO, allowing us to support drug programs from candidate selection through commercial supply.
Latest updates
-
NewsEmplicure AB Announce Completion of Phase I PK study for EMPLI03 with Quotient SciencesEmplicure AB reported dosing in the first Phase I pharmacokinetic study for EMPLI03, intended for the treatment of moderate to severe pain. The program is supported by Quotient Sciences Translational Pharmaceutics® platform.
-
Nov 29ExhibitionBiofit Conference 2022Quotient Sciences will be attending the BioFit 2022 conference. Join us!
-
WebinarStreamlining the Delivery of 14C Human ADME Data: An ADME Q&A RoundtableOn December 6, 2022, join Quotient Sciences and The Netherlands Organization for Applied Scientific Research (TNO) for an interactive, hour-long live Q&A webinar focused on streamlining human ADME studies.
-
NewsOxilio and Quotient Sciences Announce Regulatory Approval for Oxilio’s OXL001 Development ProgramOxilio and Quotient Sciences announced an update on the development of Oxilio’s OXL001 product, which uses Quotient Sciences’ Translational Pharmaceutics® platform.
Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.